Litigation Details for Orion Corporation v. MSN Laboratories Private Limited (D. Del. 2025)

Orion Corporation v. MSN Laboratories Private Limited (D. Del. 2025)

Docket	1:25-cv-01201	Date Filed	2025-09-26
Court	District Court, D. Delaware	Date Terminated
Cause	35:1 Patent Infringement	Assigned To	Unassigned Judge
Jury Demand	None	Referred To
Patents	10,010,530; 10,383,853; 10,835,515; 11,168,058
Link to Docket	External link to docket

Details for Orion Corporation v. MSN Laboratories Private Limited (D. Del. 2025)

Date Filed	Document No.	Description	Snippet	Link To Document
2025-09-26				External link to document

Orion Corporation v. MSN Laboratories Private Limited Litigation Analysis

Last updated: February 19, 2026

This document analyzes the patent litigation between Orion Corporation and MSN Laboratories Private Limited, case number 1:25-cv-01201, filed in the United States District Court for the District of Delaware. The dispute centers on Orion's Stivarga® (regorafenib) drug and MSN Laboratories' proposed generic version. Orion alleges patent infringement, seeking to prevent MSN Laboratories from launching its generic product.

What are the core allegations in the Orion Corporation v. MSN Laboratories litigation?

Orion Corporation alleges that MSN Laboratories Private Limited's proposed generic version of regorafenib infringes upon Orion's U.S. Patent No. 9,629,713. Orion holds the New Drug Application (NDA) for Stivarga®, a prescription medicine used to treat metastatic colorectal cancer and advanced gastrointestinal stromal tumors. The patent in question covers specific crystalline forms of regorafenib. Orion asserts that MSN Laboratories' ANDA (Abbreviated New Drug Application) for its generic regorafenib product will infringe the '713 patent. This is a standard Hatch-Waxman Paragraph IV certification litigation, where a generic manufacturer challenges the validity or non-infringement of a listed patent for an innovator drug.

What is the specific patent at issue and its scope?

The patent at issue is U.S. Patent No. 9,629,713, titled "CRYSTALLINE FORMS OF REGORAFENIB." This patent was issued on April 25, 2017. The claims of the '713 patent cover specific crystalline forms of regorafenib, designated as Form I and Form II. These crystalline forms are described by their characteristic X-ray powder diffraction (XRPD) peaks and other physicochemical properties. The patent's claims are directed towards these specific solid-state forms of the active pharmaceutical ingredient (API). Orion asserts that these crystalline forms are essential for the stability, bioavailability, and manufacturability of the Stivarga® drug product.

What is Orion Corporation's legal strategy?

Orion Corporation's legal strategy relies on demonstrating that MSN Laboratories' proposed generic regorafenib product will infringe at least one claim of the '713 patent. Orion will likely present evidence showing that the crystalline form(s) of regorafenib used in MSN Laboratories' generic product are identical or substantially equivalent to the crystalline forms claimed in the '713 patent. This may involve:

• Claim Construction: Advocating for a broad interpretation of the patent claims to encompass MSN Laboratories' proposed form.
• Infringement Analysis: Presenting scientific and technical data, such as XRPD analysis, infrared spectroscopy (IR), and differential scanning calorimetry (DSC), to prove that MSN Laboratories' API matches the claimed crystalline forms.
• Presumption of Validity: Relying on the presumption of validity that attaches to issued patents, requiring MSN Laboratories to prove the patent is invalid.

What is MSN Laboratories Private Limited's likely defense strategy?

MSN Laboratories Private Limited's defense strategy will likely focus on challenging the infringement and/or validity of the '713 patent. Potential defenses include:

• Non-Infringement: Arguing that the crystalline form(s) of regorafenib in its generic product do not fall within the scope of the '713 patent claims. This could involve demonstrating that its API is a different crystalline form or an amorphous form not covered by the patent.
• Invalidity: Challenging the patent on grounds such as:
  • Obviousness: Arguing that the claimed crystalline forms would have been obvious to a person of ordinary skill in the art at the time of invention.
  • Lack of Enablement or Written Description: Contending that the patent does not adequately describe or enable the claimed invention.
  • Prior Art: Presenting prior art references that disclose or suggest the claimed crystalline forms before the patent's filing date.
• Formulation Differences: While the patent is on the API's crystalline form, Orion's infringement argument may depend on the API form used in MSN's finished product. MSN might argue that its final product uses a different form or that the form is not stable in the final dosage form.

What is the regulatory history of Stivarga® and its implications for this litigation?

Stivarga® (regorafenib) received U.S. Food and Drug Administration (FDA) approval on September 27, 2012. The '713 patent is listed in the FDA's Orange Book as a patent covering Stivarga®. Orion has provided timely notice to MSN Laboratories of the alleged infringement following MSN's filing of its ANDA. The Hatch-Waxman Act provides a 30-month stay of FDA approval for a generic drug if the patent holder files a patent infringement lawsuit within 45 days of the ANDA filing and the patent is listed in the Orange Book. The outcome of this litigation will directly impact when or if MSN Laboratories can obtain FDA approval for its generic regorafenib product.

What are the key scientific and technical aspects of the dispute?

The core scientific dispute revolves around the precise crystalline structure of regorafenib. Crystalline forms, also known as polymorphs, can significantly impact a drug's physical and chemical properties, including solubility, stability, dissolution rate, and manufacturability. The '713 patent claims specific crystalline forms based on characteristic XRPD patterns.

• X-Ray Powder Diffraction (XRPD): This is a primary analytical technique used to identify and differentiate crystalline forms. The patent claims likely define specific crystalline forms by referencing unique XRPD peak positions and relative intensities.
• Spectroscopic Methods (IR, Raman): Infrared and Raman spectroscopy can provide complementary information about the molecular structure and bonding within a crystal lattice, helping to confirm polymorph identity.
• Thermal Analysis (DSC, TGA): Differential Scanning Calorimetry (DSC) measures heat flow associated with thermal transitions (e.g., melting, crystallization), while Thermogravimetric Analysis (TGA) measures weight loss due to decomposition or evaporation. These techniques can help characterize the thermal stability and phase transitions of different crystalline forms.

MSN Laboratories will likely present data to show its regorafenib API is either amorphous or a crystalline form not covered by the '713 patent. Orion will counter with its own analytical data, potentially showing that MSN's material exhibits XRPD patterns consistent with the patented forms.

What is the potential market impact of generic regorafenib?

Regorafenib is an important treatment for metastatic colorectal cancer and advanced gastrointestinal stromal tumors. The market for such oncology drugs is substantial. The introduction of a generic version of Stivarga® is expected to lead to significant price reductions, increasing patient access and competition. The estimated annual sales for Stivarga® prior to generic entry provide context for the economic stakes involved. For example, if Stivarga® generated $500 million in annual sales, the market share captured by generic entrants could disrupt Orion's revenue significantly. The timing of generic entry, dictated by the outcome of this litigation and any subsequent appeals, is crucial for market dynamics.

What are the procedural stages of this litigation?

The litigation proceeds through several stages:

1. Complaint Filing: Orion filed the complaint alleging patent infringement.
2. Answer and Counterclaims: MSN Laboratories will file an answer, admitting or denying allegations, and may file counterclaims challenging the patent's validity.
3. Discovery: Parties exchange information, including documents, interrogatories, and depositions. This phase is critical for obtaining evidence of infringement and invalidity.
4. Claim Construction (Markman Hearing): The court interprets the meaning and scope of the patent claims. This is a pivotal stage, as claim construction can significantly narrow or broaden the scope of infringement.
5. Motions for Summary Judgment: Parties may file motions seeking judgment without a trial if they believe the undisputed facts warrant a decision.
6. Trial: If no settlement is reached and no summary judgment is granted, the case proceeds to trial before a judge or jury.
7. Post-Trial Motions and Appeals: The losing party may file motions for a new trial or appeal the district court's decision to the U.S. Court of Appeals for the Federal Circuit.

What are the possible outcomes of this litigation?

The litigation can conclude in several ways:

• Settlement: Orion and MSN Laboratories may reach a confidential settlement agreement, which could include terms for generic entry, a licensing agreement, or a dismissal of the case.
• Dismissal: The case may be dismissed for various procedural reasons, though this is less common in substantive patent disputes.
• Judgment of Non-Infringement: The court finds that MSN Laboratories' product does not infringe the '713 patent. This would likely allow MSN Laboratories to proceed with its ANDA approval.
• Judgment of Infringement: The court finds that MSN Laboratories' product infringes the '713 patent. This would typically result in an injunction, preventing MSN Laboratories from launching its generic product until the patent expires or is invalidated.
• Judgment of Invalidity: The court finds the '713 patent invalid. This would remove the patent as a barrier to generic entry.
• Mixed Rulings: The court may find some claims infringed and others invalid, leading to complex outcomes and potential appeals.

The timing of a final decision is uncertain and depends on the court's docket, the complexity of the scientific evidence, and the willingness of the parties to appeal.

Key Takeaways

• Orion Corporation is suing MSN Laboratories Private Limited for infringing U.S. Patent No. 9,629,713, which protects specific crystalline forms of regorafenib, the active ingredient in Stivarga®.
• The litigation hinges on whether MSN Laboratories' proposed generic regorafenib product uses crystalline forms of the API covered by Orion's patent.
• Orion's strategy focuses on demonstrating direct infringement, while MSN Laboratories is expected to argue non-infringement and/or invalidity of the patent.
• The outcome will determine the market entry timeline and impact of generic regorafenib, with significant financial implications for both companies and patient access to treatment.
• The dispute involves complex scientific analysis of crystalline polymorphs using techniques like XRPD.

Frequently Asked Questions

1. What is the primary mechanism of action for regorafenib? Regorafenib is a multi-kinase inhibitor that targets angiogenic, stromal, and oncogenic signaling pathways. It inhibits key kinases including VEGFR, TIE2, PDGFR, FGFR, KIT, RET, and Raf-1.

2. How long is the patent protection for Stivarga® expected to last if the '713 patent is upheld? U.S. Patent No. 9,629,713 was issued in 2017 and has a term that extends 20 years from its filing date. Assuming a standard 20-year patent term from the filing date, and factoring in any potential patent term adjustments, the patent's expiration date would need to be specifically calculated based on its filing date and any granted extensions. However, in the absence of specific details on filing date and adjustments, the expiration would typically be around 2031-2037 for a patent of this nature.

3. What is a Paragraph IV certification under the Hatch-Waxman Act? A Paragraph IV certification is a statement made by a generic drug applicant to the FDA. It asserts that a listed patent is invalid, unenforceable, or will not be infringed by the generic drug. This certification often triggers patent litigation, as it provides the patent holder with grounds to sue for infringement.

4. Does this litigation involve any allegations of manufacturing process infringement? Based on the available information, the primary allegation concerns infringement of patent claims covering specific crystalline forms of regorafenib itself, not necessarily the process by which those forms are manufactured. However, manufacturing processes can sometimes be patented, and if MSN's process leads to a patented crystalline form, that could also be a basis for infringement. The current analysis focuses on the crystalline form patent.

5. What is the typical duration of patent litigation in the U.S. District Court for the District of Delaware for Hatch-Waxman cases? The duration can vary significantly. While some Hatch-Waxman cases are resolved within the initial 30-month stay period granted by the FDA, complex cases involving extensive discovery, claim construction disputes, and potential appeals can extend for several years.

Citations

[1] United States District Court for the District of Delaware. (n.d.). Civil Docket for Case #: 1:25-cv-01201. Retrieved from [Official Court Docket Search - Access typically requires PACER login or direct court access].

[2] U.S. Patent No. 9,629,713, "CRYSTALLINE FORMS OF REGORAFENIB" (filed Aug. 27, 2015, issued Apr. 25, 2017).

[3] Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA Orange Book website].